NCT05813457Recruiting
Impact of an Early Identification Program for First-Episode Psychosis on the Duration of Untreated Psychosis
Impact of an Early Identification Program for First-Episode Psychosis on the Duration of Untreated Psychosis. Multicenter, Randomized Stepped-wedge Study
Source: ClinicalTrials.gov · Last updated 24 Nov 2025
Brief summary (registry, in English)
The First-Episode Psychosis (FPE) is a severe disorder that can include delusions, cognitive disorders and suicidal behavior. In the majority of cases (more than 80%) it evolves into schizophrenia. Numerous studies show that the rapidity of the initial management of FPE would reduce the risk of negative evolution and would have a decisive impact on the short and long term prognosis. The rapidity of this management can be measured by the duration of untreated psychosis, or DUP (Duration of Untreated Psychosis), the time interval between the appearance of the first frank psychotic symptoms and the initiation of adequate psychiatric care. The objective of this study is to show the impact of an intervention facilitating access to specialized care for PEP on the reduction of DUP. This intervention consists of an early identification program for FPE, the PRESTO program, specifically targeting 3 determining steps in the reduction of DUP: * Informing the general population about psychotic disorders * Knowledge of front line actors (APL: general practitioners, school and university medicine, teenager's house, associative networks educators, emergency services, firefighters, etc.) about FPE and its management * Articulation between APL and specialized psychiatric care
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 416 (estimated)
- First submitted
- 3 Apr 2023
- Start date
- 6 Jun 2023
- Primary completion date
- Feb 2027
- Lead sponsor
- Centre Hospitalier Universitaire de Saint Etienne
- Diseases
- Schizophrenia
- NCT number
- NCT05813457
What you commit to
- Study type: Interventional
- Planned participants: 416
- From 6 Jun 2023 to the primary completion date, Feb 2027
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients already treated and followed for FPE
- Brief psychotic state not requiring specific management
Who the study is looking for
- Patients with a diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, or brief psychotic disorder established according to DMS 5
- Never having taken neuroleptic treatment for antipsychotic purposes, except for the current episode and for a duration of \< 6 month
- Oral consent of the patient or, for minors, of his/her parents to participate in the study
Age in the registry: 15 years to 35 years · Sex: All · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospices Civils de Lyon Coordinator of this site? Confirm its status | Bron | France | Recruiting |
| CHU Clermont-Ferrand Coordinator of this site? Confirm its status | Clermont-Ferrand | France | Recruiting |
| Chu Grenoble Coordinator of this site? Confirm its status | Grenoble | France | Recruiting |
| CHU de Montpellier Coordinator of this site? Confirm its status | Montpellier | France | Recruiting |
| CHU de Nîmes Coordinator of this site? Confirm its status | Nîmes | France | Recruiting |
| CHU Saint-Etienne Coordinator of this site? Confirm its status | Saint-Etienne | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.